Pfizer Ltd. — Regulatory Filings 2020

Nov 26, 2020

Limited

The Capital, 1802 / 1901, Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051. Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

November 26, 2020

The Corporate Relationship Dept. BSE Limited 1st Floor, P.J.Towers Dalal Street, Fort Mumbai - 400 001 Scrip Code: 500680

The Manager, Listing Dept. The National Stock Exchange of India Ltd. Exchange Plaza, 5th Floor, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E) Mumbai - 400 051 Scrip Symbol: PFIZER

Dear Sirs,

Sub: Disclosure under Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')

Pursuant to Regulation 23(9) of the Listing Regulations, please find enclosed, disclosure of related party transactions, in the format specified in the accounting standards for the half year ended September 30, 2020.

The said disclosure is also available on the website of the Company i.e., www.pfizerindia.com

Please take the above on record.

Thanking you,

Yours truly, For Pfizer Limited

Prajeet Nair Company Secretary

Encl: A/a

CIN: L24231MH1950PLC008311

contactus.india@pfizer.com

www.pfizerindia.com

Pfizer Limited

DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2020

Currency: ₹ in crore

Related party transactions

I. Names of related parties and description of relationships

A. Parties where control exists:

Ultimate holding company: Pfizer Inc., USA

B. Companies collectively exercising significant influence:

Pfizer East India B.V., Netherlands Wyeth LLC, USA Wyeth Holdings Corporation, USA John Wyeth & Brother Limited, UK Warner - Lambert Company, LLC, USA Parke - Davis & Company, LLC, USA Pharmacia Corporation, USA [Collectively holding 63.92% of the aggregate of equity share capital of the Company]

C. Fellow subsidiaries with whom transactions have taken place during the half year/ year end

Pfizer Products India Private Limited, India Pfizer Innovative Supply Point International BVBA, Belgium Pfizer Service Company BVBA, Belgium Pfizer Worldwide Services, Ireland Pfizer Asia Manufacturing PTE, Singapore Pfizer Canada Inc

D. Key managerial personnel

Mr. S. Sridhar - Managing Director Mr. Milind Patil - Wholetime Director & Chief Financial Officer Mr. Vivek Dhariwal - Wholetime Director (upto 14 February 2020) Mr. Samir Kazi (w.e.f 14 February 2020) Mr. R A Shah - Independent Director Mr. Pradip Shah - Independent Director Mr. Uday Khanna - Independent Director Mr. Sunil Lalbhai - Independent Director Ms.Meena Ganesh - Independent Director

E. Relative of Key managerial personnel

Mr. Akhilesh Iyer (upto 30 June 2020)

Pfizer Limited

DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2020

Currency: ₹ in crore

Transactions during the half year and balances outstanding as at the half year ended September 30, 2020 with the related parties are as follows:

30 September 2020			31 March 2020
No. Nature of transactions	Ultimateholdingcompany	Companiesexercisingsignificant influence	Fellowsubsidiaries	Total	Ultimateholdingcompany	Companiesexercisingsignificantinfluence	Fellowsubsidiaries	Total
1 Service income	-	-	22.89	22.89	-	-	55.19	55.19
2 Recovery of expenses	-	-	0.12	0.12	0.54	0.03	0.19	0.73
3 Purchase of stock-in-trade	-	-	180.88	180.88	-	-	393.41	393.41
4 Purchase of raw / bulk materials	-	-	10.22	10.22	-	-	115.05	115.05
5 Dividend in respect of the year ended 31 March 2020/ 2019	-	965.02	-	965.02	-	65.77	-	65.77
6 Asset transfer	-	2.12		2.12	-	1.42	8.59	10.01
	30 September 2020			31 March 2020
No. Nature of transactions	Ultimateholdingcompany	Companiesexercisingsignificant influence	Fellowsubsidiaries	Total	Ultimateholdingcompany	Companiesexercisingsignificantinfluence	Fellowsubsidiaries	Total
8 Outstanding as at the half year / year end – Due from	-	0.09	9.52	9.61	0.54	0.09	20.99	21.62
9 Outstanding as at the half year / year end – Due to	11.05	6.46	138.43	155.94	11.18	6.47	271.20	288.85

Key managerial personnel

	No. Nature of transactions	Half Yearended30	Year ended31 March 2020
		September
1	Remuneration to key management personnel *	5.47	9.22

* Excludes amounts payable to key management personnel towards gratuity and compensated absences.

Details of material transactions:

		Half Year	Year ended
		ended	31 March 2020
		30
		September
a)	Service income
	Pfizer Products India Private Limited	10.81	25.60
	Pfizer Worldwide Services	12.09	29.59
b)	Recovery of expenses
	Pfizer Products India Private Limited	0.12	0.19
	Pfizer Inc., USA	-	0.54
c)	Purchase of stock in trade
	Pfizer Innovative Supply Point Intl BVBA, Belgium	17.25	66.07
	Pfizer Service Company BVBA, Belgium	163.63	327.34
d)	Purchase of raw/ bulk materials
	Pfizer Service Company BVBA, Belgium	6.79	111.62
e)	Dividend paid
	Pfizer East India B.V.	600.15	40.92
	Wyeth LLC, USA	185.38	12.64
g)	Remuneration to key management personnel
	S. Sridhar	2.57	4.11
	Milind Patil	1.61	2.10
	Vivek Dhariwal (Upto 14 February 2020)	-	1.88
	Samir Kazi (w.e.f 14 February 2020)	0.88	0.16

Pfizer Limited

DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2020

Currency: ₹ in crore

Related party transactions (Continued)

		Half Year	As on
		ended	31 March 2020
		30 September
		2020
h)	Outstanding as at the half year/ year end due from
	Pfizer Worldwide Services	2.56	5.70
	Pfizer Products India Private Limited, India	6.96	15.29
i)	Outstanding as at the half year/ year end due to
	Pfizer Innovative Supply Point Intl BVBA, Belgium	11.51	15.81
	Pfizer Service Company BVBA, Belgium	26.15	152.55
	Pfizer Export Company, Ireland	82.43	82.85